AG
RVNC

Advisor Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Advisor Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$4K Buy
+275
New +$4.26K ﹤0.01% 4790
2016
Q4 		– Sell
-604
Closed -$10K – 4644
2016
Q3 		$10K Buy
604
+504
+504% +$7.32K ﹤0.01% 3570
2016
Q2 		$1K Buy
+100
New +$1.77K ﹤0.01% 4287

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Advisor Group's RVNC Position: Q4 2019 in Review

Advisor Group opened a new position in Revance Therapeutics, Inc. (RVNC) in Q4 2019: 275 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #4790 among its holdings. This is a return to the name: Advisor Group previously reported a position in RVNC as recently as Q3 2016.

Advisor Group first reported a position in RVNC in Q2 2016 and has held it in 3 quarters since. The position peaked at $10K in Q3 2016. 134 funds tracked by Wall St. Rank hold RVNC as of Q4 2019.

  • Advisor Group held 275 shares of Revance Therapeutics, Inc. worth $4K as of Q4 2019.
  • Revance Therapeutics, Inc. was a new Advisor Group position in Q4 2019.
  • Revance Therapeutics, Inc. made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4790 holding.
  • Advisor Group first reported a position in Revance Therapeutics, Inc. in Q2 2016 and has held it in 3 quarters since.
  • Advisor Group's Revance Therapeutics, Inc. position peaked at $10K in Q3 2016.
  • 134 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.